Presentation

W4-2 Mucosal Immunity: What’s special about it and can vaccines induce it?

Peter Openshaw

GVIRF 2023 Presentation

Authors

Languages

  • English

Publication year

2023

Type

Presentation

Categories

  • Global initiatives

GVIRF-2023

This resource appears in the following Hot Topic page:

The resource is included in the following table:

TitleAuthorYearTypeLanguage
P8 - Reflections and closing remarks: Progress and the path forwardNoni MacDonald, Dalhousie U.2023WebinarEnglish
GVIRF 2023 Welcome and Opening RemarksLee Hall2023WebinarEnglish
Keynote 1 - Vaccines in the Post-COVID Era: Can Policy and Practice Keep up with ScienceBarney Graham2023WebinarEnglish
P2 - Lessons from COVID-19 vaccines and future pandemic preparednessCharlie Weller2023WebinarEnglish
W8 - Select poster highlightsPeter Dull, Sinead Delany-Moretlwe2023WebinarEnglish
P5-3 Using mHealth Interventions to Improve Vaccination CoverageAbdul Momin Kazi2023PresentationEnglish
W7 - New vaccines on the horizonAlejandro Cravioto, Shahida Baqar2023WebinarEnglish
P6 - Vaccine technologies for equityPhilippe-Alexandre Gilbert2023WebinarEnglish
W5 - Vaccine development strategies at the intersection of market model, value drivers, and access policyJessica Martinez, Raman Rao2023WebinarEnglish
W4 - Mucosal immunity and vaccinesMelanie Saville2023WebinarEnglish
P3 - Current status of R&D for HIV, TB, Malaria, and Universal Influenza vaccines (and reports from Workshops 1-3)Annie Mo, Jerome Kim2023WebinarEnglish
W3 - Regional manufacturingMartin Friede2023WebinarEnglish
W2 - Novel vaccine platformsMax Silverman, Sue Ann Clemens2023WebinarEnglish
W1 - Immunological and Vaccine Considerations for Special Populations: women of reproductive age and pregnancy, people living with HIV, and older adultsCarolyn Deal, Ruth Karron2023WebinarEnglish
P6-3 A low footprint vaccine manufacturing platform for in-country, for-country productionMathias Garny2023PresentationEnglish
P5-4 Strengthening Routine Immunization: Use of Reaching Every District - Quality Improvement (RED-QI) approachMelkamu Ayalew2023PresentationEnglish
W8-9 Polyvalent strategy to the development of broadly protective vaccines against COVID-19 subvariantsChang-Yuil Kang2023PresentationEnglish
W8-8 The landscape of infectious disease exposure over the past two decades in the Kenyan coastTimothy Chege2023PresentationEnglish
W8-7 RV 460 Study: Comparative Adjuvant Study or HIV Env-C DNA and Protein Vaccines in KenyaJosphat Kiprop Kosgei2023PresentationEnglish
W8-6 Nucleoprotein Antigen Adjuvanted with Liposomal Cholesterol-linked TLR7/8 Agonist Showed Protective Immunity in Influenza Mouse ModelChul Kim2023PresentationEnglish
W8-4 Innovative DDS "DegradaBALL" for mRNA vaccine against next pandemics: "100 days mission"Dal-Hee Min2023PresentationEnglish
W8-5 Cross-neutralization of Influenza A by SARS-CoV-2 antibodiesMohammad Mamun Alam2023PresentationEnglish
W8-3 High prevalence of rotavirus infection among under five children despite a high rotavirus vaccination coverage in EthiopiaDebasu Damtie2023PresentationEnglish
W8-2 Changing the HPV Landscape with Indigenous Vaccine: CERVAVACHitt Sharma2023PresentationEnglish
W8-1 Workshop 8: Select Poster HighlightsPeter Dull2023PresentationEnglish
W7-4 Enteric Disease: Shigella and ETEC Vaccine DevelopmentMichelo Simuyandi2023PresentationEnglish
W7-3 2023: the year of RSVRuth Karron2023PresentationEnglish
W7-2 Dengue VaccinesAnnelies Wilder-Smith2023PresentationEnglish
W6-5 Protecting young infants through immunopreventionJessica Fleming2023PresentationEnglish
W6-4 Reaching adolescent girls with the HPV vaccineCathy Ndiaye2023PresentationEnglish
W6-3 Implementation research needs on vaccine delivery according to epidemiological contextHalidou Tinto2023PresentationEnglish
W6-1 What is implementation research and why is it important?Alexander Rowe2023PresentationEnglish
W5-5 Developing vaccines as global public good: RIGHT foundation’s approachHani Kim2023PresentationEnglish
W5-4 The Next Frontier in Defining Value: Health Economics in LMICsAlice Chen2023PresentationEnglish
W4-6 A translational Research Institute focused on vaccines and airway immunityPeter Andersen2023PresentationEnglish
W4-5 mRNA-lipid nanoparticle vaccines for intranasal deliveryDarin Edwards2023PresentationEnglish
W4-4 Adenovirus Vector Based Covid-19 Inhalation VaccineChunlin Xin2023PresentationEnglish
W4-3 A Mucosally-delivered Newcastle Disease Virus-vectored Booster Vaccine to Prevent SARS-CoV-2 Breakthrough Infection and TransmissionMichael Egan2023PresentationEnglish
W4-2 Mucosal Immunity: What’s special about it and can vaccines induce it?Peter Openshaw2023PresentationEnglish
W4-1 Mucosal Immunity: Opening RemarksMelanie Saville2023PresentationEnglish
W3-5 The case for globally distributed vaccine manufacturing - CEPI perspectiveMelanie Saville2023PresentationEnglish
W2-3 mRNA and adjuvants friends…or foes ?Nathalie Garcon2023PresentationEnglish
W3-4 Gavi’s Strategy to Support Regional ManufacturingMarta Tufet2023PresentationEnglish
W3-3 Biological E. LimitedMahima Datla2023PresentationEnglish
W3-2 An African Mission - Establish and SustainPatrick Tippoo2023PresentationEnglish
W2-5 New Developments in Viral Vector VaccinesJerry Sadoff2023PresentationEnglish
W2-4 Nanoparticle Vaccines: A success story for viral vaccine developmentHarry Kleanthous2023PresentationEnglish
W1-5 COVID 19 vaccine effectiveness in the elderly populationTarun Saluja2023PresentationEnglish
W1-4 TB Vaccine Roadmap for People Living with HIVMindy Miner2023PresentationEnglish
W1-3 Group B Streptococcus Vaccination in Pregnant WomenAnna Seale2023PresentationEnglish

Added by: Angela Hwang

Added on: 2023-04-02 02:45:06

Hits: 1292

Uploaded file

W4-2 Openshaw.pdf

Click to Download

Add resource